Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: D1532C00079:A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients Receiving Second-Line Treatment for KRAS Mutation-

 


D1532C00079:A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients Receiving Second-Line Treatment for KRAS Mutation-


Trial Focus

Lung Cancer

Objective

         This is a clinical trial of investigational drug Selumetinib which will be administered orally, in combination with Docetaxel.

IRB Protocol #

13-2647

Trial Status

OPEN

Principle Investigator

ROBERT DOEBELE

Sponsor

AstraZeneca

Contact

MICHAEL CROSS at (720)848-0592 or MICHAEL.CROSS@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. You will first go through several tests and procedures to make sure that you are eligible to take part in the study. This study will have 2 different groups of research subjects like you. Group 1 will receive the study drug and docetaxel. Group 2 will receive a placebo and docetaxel. // Eligibility criteria include but are not limited to 18 years or older with KRAS Mutation- Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB - IV).Eligibility criteria include but are not limited to 18 years or older with KRAS Mutation- Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB - IV).